Lexaria Bioscience Corp.

LEXX


Canadian symbol: LEXX
US symbol: LEXX

Currency in USD

Valuation Measures4

Market Cap (intraday) 13.05M
Enterprise Value 9.54M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)37.35
Price/Book (mrq)2.62
Enterprise Value/Revenue 27.46
Enterprise Value/EBITDA -1.39

Trading Information

Stock Price History

Beta (5Y Monthly) 1.08
52-Week Change 3-61.76%
S&P500 52-Week Change 31.77%
52 Week High 33.6000
52 Week Low 30.6500
50-Day Moving Average 31.8278
200-Day Moving Average 32.4728

Share Statistics

Avg Vol (3 month) 3141.18k
Avg Vol (10 day) 3546.97k
Shares Outstanding 58.09M
Implied Shares Outstanding 6N/A
Float 84.71M
% Held by Insiders 118.40%
% Held by Institutions 111.69%
Shares Short (May 14, 2023) 4260.09k
Short Ratio (May 14, 2023) 42.04
Short % of Float (May 14, 2023) 43.48%
Short % of Shares Outstanding (May 14, 2023) 43.21%
Shares Short (prior month Apr 13, 2023) 4317.94k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3Jan 11, 2021
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Aug 30, 2022
Most Recent Quarter (mrq)Feb 27, 2023

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-2,018.51%

Management Effectiveness

Return on Assets (ttm)-53.87%
Return on Equity (ttm)-88.46%

Income Statement

Revenue (ttm)347.36k
Revenue Per Share (ttm)0.06
Quarterly Revenue Growth (yoy)14.20%
Gross Profit (ttm)183.56k
EBITDA -6.91M
Net Income Avi to Common (ttm)-6.9M
Diluted EPS (ttm)-1.1900
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)3.54M
Total Cash Per Share (mrq)0.59
Total Debt (mrq)29.08k
Total Debt/Equity (mrq)0.63
Current Ratio (mrq)17.94
Book Value Per Share (mrq)0.84

Cash Flow Statement

Operating Cash Flow (ttm)-4.91M
Levered Free Cash Flow (ttm)-1.8M

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Cannabis Market and Business News

Real-time cannabis business news from hundreds of sources. Never miss the news that matters the most.




Company News Date
LEXX
Lexaria Bioscience
5 days ago
LEXX
Lexaria Bioscience
1 week ago
LEXX
Lexaria Bioscience
1 week ago
LEXX
Lexaria Bioscience
1 week ago
LEXX
Lexaria Bioscience
2 weeks ago
LEXX
Lexaria Bioscience
2 weeks ago
LEXX
Lexaria Bioscience
3 weeks ago
LEXX
Lexaria Bioscience
3 weeks ago
LEXX
Lexaria Bioscience
1 month ago
LEXX
Lexaria Bioscience
2 months ago
LEXX
Lexaria Bioscience
2 months ago
LEXX
Lexaria Bioscience
3 months ago
LEXX
Lexaria Bioscience
3 months ago
LEXX
Lexaria Bioscience
4 months ago
LEXX
Lexaria Bioscience
4 months ago
LEXX
Lexaria Bioscience
4 months ago
LEXX
Lexaria Bioscience
4 months ago
LEXX
Lexaria Bioscience
5 months ago
LEXX
Lexaria Bioscience
5 months ago
LEXX
Lexaria Bioscience
6 months ago
LEXX
Lexaria Bioscience
6 months ago
LEXX
Lexaria Bioscience
6 months ago
LEXX
Lexaria Bioscience
8 months ago
LEXX
Lexaria Bioscience
8 months ago
LEXX
Lexaria Bioscience
9 months ago
LEXX
Lexaria Bioscience
9 months ago
LEXX
Lexaria Bioscience
10 months ago
LEXX
Lexaria Bioscience
10 months ago
LEXX
Lexaria Bioscience
10 months ago
LEXX
Lexaria Bioscience
11 months ago
LEXX
Lexaria Bioscience
1 year ago
LEXX
Lexaria Bioscience
1 year ago
LEXX
Lexaria Bioscience
1 year ago
LEXX
Lexaria Bioscience
1 year ago
LEXX
Lexaria Bioscience
1 year ago
LEXX
Lexaria Bioscience
1 year ago
LEXX
Lexaria Bioscience
1 year ago
LEXX
Lexaria Bioscience
1 year ago
LEXX
Lexaria Bioscience
1 year ago
LEXX
Lexaria Bioscience
1 year ago
LEXX
Lexaria Bioscience
1 year ago
LEXX
Lexaria Bioscience
1 year ago
LEXX
Lexaria Bioscience
1 year ago
LEXX
Lexaria Bioscience
1 year ago
LEXX
Lexaria Bioscience
1 year ago
LEXX
Lexaria Bioscience
1 year ago
LEXX
Lexaria Bioscience
1 year ago
LEXX
Lexaria Bioscience
1 year ago
LEXX
Lexaria Bioscience
1 year ago
LEXX
Lexaria Bioscience
1 year ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
3 years ago
LEXX
Lexaria Bioscience
3 years ago
LEXX
Lexaria Bioscience
3 years ago
LEXX
Lexaria Bioscience
3 years ago
LEXX
Lexaria Bioscience
3 years ago
LEXX
Lexaria Bioscience
3 years ago
LEXX
Lexaria Bioscience
3 years ago
LEXX
Lexaria Bioscience
3 years ago
LEXX
Lexaria Bioscience
3 years ago
LEXX
Lexaria Bioscience
3 years ago
LEXX
Lexaria Bioscience
3 years ago
LEXX
Lexaria Bioscience
3 years ago
LEXX
Lexaria Bioscience
3 years ago
LEXX
Lexaria Bioscience
3 years ago
LEXX
Lexaria Bioscience
3 years ago
LEXX
Lexaria Bioscience
3 years ago
LEXX
Lexaria Bioscience
3 years ago
LEXX
Lexaria Bioscience
3 years ago
LEXX
Lexaria Bioscience
3 years ago
LEXX
Lexaria Bioscience
3 years ago
LEXX
Lexaria Bioscience
3 years ago
LEXX
Lexaria Bioscience
3 years ago
LEXX
Lexaria Bioscience
3 years ago
LEXX
Lexaria Bioscience
3 years ago
LEXX
Lexaria Bioscience
3 years ago
LEXX
Lexaria Bioscience
3 years ago
LEXX
Lexaria Bioscience
3 years ago
LEXX
Lexaria Bioscience
3 years ago
LEXX
Lexaria Bioscience
3 years ago
LEXX
Lexaria Bioscience
3 years ago
LEXX
Lexaria Bioscience
3 years ago
LEXX
Lexaria Bioscience
3 years ago
LEXX
Lexaria Bioscience
3 years ago
LEXX
Lexaria Bioscience
3 years ago
LEXX
Lexaria Bioscience
3 years ago
LEXX
Lexaria Bioscience
4 years ago
LEXX
Lexaria Bioscience
4 years ago
LEXX
Lexaria Bioscience
4 years ago
LEXX
Lexaria Bioscience
4 years ago
LEXX
Lexaria Bioscience
4 years ago
LEXX
Lexaria Bioscience
4 years ago
LEXX
Lexaria Bioscience
4 years ago
LEXX
Lexaria Bioscience
4 years ago
LEXX
Lexaria Bioscience
4 years ago
LEXX
Lexaria Bioscience
4 years ago
LEXX
Lexaria Bioscience
4 years ago
LEXX
Lexaria Bioscience
4 years ago
LEXX
Lexaria Bioscience
4 years ago
LEXX
Lexaria Bioscience
4 years ago
LEXX
Lexaria Bioscience
4 years ago
LEXX
Lexaria Bioscience
4 years ago
LEXX
Lexaria Bioscience
4 years ago
LEXX
Lexaria Bioscience
4 years ago
LEXX
Lexaria Bioscience
4 years ago
LEXX
Lexaria Bioscience
4 years ago
LEXX
Lexaria Bioscience
4 years ago

Currency in USD
Earnings EstimateCurrent Qtr. (Nov 2022)Next Qtr. (Feb 2023)Current Year (2023)Next Year (2024)
No. of Analysts0011
Avg. Estimate00-1.07-0.84
Low Estimate00-1.07-0.84
High Estimate00-1.07-0.84
Year Ago EPS-0.22-0.25-1.24-1.07
Revenue EstimateCurrent Qtr. (Nov 2022)Next Qtr. (Feb 2023)Current Year (2023)Next Year (2024)
No. of Analysts0011
Avg. EstimateN/AN/A450k1.13M
Low EstimateN/AN/A450k1.13M
High EstimateN/AN/A450k1.13M
Year Ago Sales14k31k255k450k
Sales Growth (year/est)N/AN/A76.50%151.10%
Earnings History2021-08-302022-02-272022-05-302022-08-30
EPS Est.-0.230.21-0.28-0.21
EPS Actual-0.22-0.25-0.41-0.24
Difference0.01-0.46-0.13-0.03
Surprise %4.30%-219.00%-46.40%-14.30%
EPS TrendCurrent Qtr. (Nov 2022)Next Qtr. (Feb 2023)Current Year (2023)Next Year (2024)
Current Estimate00-1.07-0.84
7 Days Ago00-1.07-0.84
30 Days Ago00-1.07-0.84
60 Days Ago00-1.04-0.87
90 Days Ago00-1.04-0.87
EPS RevisionsCurrent Qtr. (Nov 2022)Next Qtr. (Feb 2023)Current Year (2023)Next Year (2024)
Up Last 7 DaysN/AN/AN/AN/A
Up Last 30 DaysN/AN/AN/AN/A
Down Last 7 DaysN/AN/AN/AN/A
Down Last 30 DaysN/AN/AN/AN/A
Growth EstimatesLEXXIndustrySector(s)S&P 500
Current Qtr.N/AN/AN/AN/A
Next Qtr.N/AN/AN/AN/A
Current Year13.70%N/AN/AN/A
Next Year21.50%N/AN/AN/A
Next 5 Years (per annum)N/AN/AN/AN/A
Past 5 Years (per annum)N/AN/AN/AN/A


Insiders transactions are updated every hour.

Major Holders

Currency in USD
Breakdown
18.40%% of Shares Held by All Insider
11.69%% of Shares Held by Institutions
14.33%% of Float Held by Institutions
19Number of Institutions Holding Shares

Top Institutional Holders

HolderSharesDate Reported% OutValue
Invenomic Capital Management, LP473,103Mar 30, 20230.59%345,838
Susquehanna International Group, LLP67,452Mar 30, 20230.08%49,307
Geode Capital Management, LLC48,837Mar 30, 20230.06%35,699
Vanguard Group, Inc. (The)33,329Mar 30, 20230.04%24,363
Dimensional Fund Advisors LP15,268Mar 30, 20230.02%11,160
Renaissance Technologies, LLC13,600Mar 30, 20230.02%9,941
Tower Research Capital LLC (TRC)4,089Mar 30, 20230.01%2,989
UBS Group AG4,639Mar 30, 20230.01%3,391
Centiva Capital, LP12,059Mar 30, 20230.01%8,815
1832 Asset Management L.P.2,686Mar 30, 20230.00%1,963

Top Mutual Fund Holders

HolderSharesDate Reported% OutValue
Northern Lights Fd Tr II-Invenomic Fd386,575Jan 30, 20230.48%282,586
Fidelity Extended Market Index Fund39,684Feb 27, 20230.05%29,009
Vanguard Extended Market Index Fund33,329Dec 30, 20220.04%24,363
DFA U.S. Core Equity 1 Portfolio6,609Jan 30, 20230.01%4,831
Fidelity Series Total Market Index Fund5,481Feb 27, 20230.01%4,006
DFA U.S. Core Equity 2 Portfolio4,587Jan 30, 20230.01%3,353
Dimensional ETF Tr-Dimensional U.S. Core Equity 2 ETF4,068Jan 30, 20230.01%2,973
Fidelity NASDAQ Composite Index Fund2,740Feb 27, 20230.00%2,002
Dimensional ETF Tr-Dimensional US Sustainability Core 1 ETF4Jan 30, 20230.00%2
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by Lexaria Bioscience Corp.


Lexaria Discovers that DehydraTECH-CBD Treatment in Hypertension Study HYPER-H21-4 Resulted in Reduction in Pro-Inflammatory Biomarkers

Lexaria Discovers that DehydraTECH-CBD Treatment in Hypertension Study HYPER-H21-4 Resulted in Reduction in Pro-Inflammatory Biomarkers

DehydraTECH-CBD offers distinctive mechanistic benefits related to its growing therapeutic utilityKELOWNA, BC / ACCESSWIRE / May 23, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce additional findings from last year's human clini... Read More...
CGMP Manufacturing Complete for Lexaria's Upcoming U.S. Phase 1b Hypertension Clinical Trial

CGMP Manufacturing Complete for Lexaria’s Upcoming U.S. Phase 1b Hypertension Clinical Trial

DehydraTECH-CBD is currently unique in its evidenced superior power to reduce blood pressure over other oral CBD formulations.DehydraTECH-CBD has demonstrated exceptional safety and tolerability and a sustained decrease in blood pressure.KELOWNA, BC / ACCESSWIRE / May 11, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "C... Read More...
Lexaria is Receiving Four New Patents

Lexaria is Receiving Four New Patents

KELOWNA, BC / ACCESSWIRE / April 20, 2023 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has received notifications of four new patents either awarded or allowed.In Japan, Lexaria has received a new patent under its Patent Family #3: Stab... Read More...
Lexaria's DehydraTECH-CBD Diabetes Study Demonstrates Weight Loss, Improved Triglyceride and Cholesterol Levels

Lexaria’s DehydraTECH-CBD Diabetes Study Demonstrates Weight Loss, Improved Triglyceride and Cholesterol Levels

KELOWNA, BC / ACCESSWIRE / March 2, 2023 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that its diabetes animal model study DIAB-A22-1 has completed and produced at least three positive outcomes including weight loss in obese diabetic-condition... Read More...
Lexaria Discovers Potential Novel Mechanism From Hypertension Study HYPER-H21-4

Lexaria Discovers Potential Novel Mechanism From Hypertension Study HYPER-H21-4

KELOWNA, BC / ACCESSWIRE / February 21, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce additional findings from its human clinical study HYPER-H21-4 ("the Study") demonstrating a potentially novel mechanism of action of its pate... Read More...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Focused on Filling Need for Hypertension Treatment Solution

Lexaria Bioscience Corp. (NASDAQ: LEXX) Focused on Filling Need for Hypertension Treatment Solution

NEW YORK, Aug. 11, 2022 -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “The Power of Science to Stop a Killer.” To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast To view the full editorial, please visit: https://nnw.fm/9kD5b In its 2021 industry ... Read More...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Stands as Global Leader in Delivery Tech Space

Lexaria Bioscience Corp. (NASDAQ: LEXX) Stands as Global Leader in Delivery Tech Space

NEW YORK, May 26, 2022 -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Nicotine Surges as Smoking Sags.” To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast To view the full editorial, please visit: https://nnw.fm/WNblw The fact remains that an est... Read More...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Offers Breakthrough Delivery Tech in Hot Nicotine Space

Lexaria Bioscience Corp. (NASDAQ: LEXX) Offers Breakthrough Delivery Tech in Hot Nicotine Space

NEW YORK, May 25, 2022 -- via InvestorWire — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities. To view the full p... Read More...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Emerging as Leader in Pursuit of More-Effective Hypertension Treatment

Lexaria Bioscience Corp. (NASDAQ: LEXX) Emerging as Leader in Pursuit of More-Effective Hypertension Treatment

NEW YORK, Sept. 16, 2021 -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Hypertension: The Silent Killer Making Loud Noise for Investors.” To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast To view the full editorial, please visit: https://nnw.fm/... Read More...
Lexaria Bioscience Corp. (NASDAQ: LEXX) on Forefront of Exciting Hypertension Innovation

Lexaria Bioscience Corp. (NASDAQ: LEXX) on Forefront of Exciting Hypertension Innovation

NEW YORK, Aug. 06, 2021 -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Cardiovascular Disease Drug Market Offers Compelling Potential for First Movers, Innovators in the Space.” To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast To view the full ... Read More...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Leads the Way in Innovating Hypertension Treatment

Lexaria Bioscience Corp. (NASDAQ: LEXX) Leads the Way in Innovating Hypertension Treatment

NEW YORK, Aug. 04, 2021 -- via InvestorWire — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities. To view the full ... Read More...
Lexaria Bioscience Corp. Discusses $11 Million Public Offering and 2021 Goals with The Stock Day Podcast

Lexaria Bioscience Corp. Discusses $11 Million Public Offering and 2021 Goals with The Stock Day Podcast

Phoenix, Arizona--(Newsfile Corp. - January 28, 2021) - The Stock Day Podcast welcomed Lexaria Bioscience Corp. (NASDAQ: LEXX) (CSE: LXX) ("the Company"), a company with the proprietary drug delivery technology, DehydraTECH™, which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream. CEO of the Company, Chris B... Read More...
Lexaria Bioscience Corp. Announces Closing of $11 Million Public Offering with Full Exercise of Underwriter Option to Purchase Additional Shares and Warrants

Lexaria Bioscience Corp. Announces Closing of $11 Million Public Offering with Full Exercise of Underwriter Option to Purchase Additional Shares and Warrants

KELOWNA, BC / ACCESSWIRE / January 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company") today announced the closing of its previously announced underwritten public offering (the "Offering") of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of com... Read More...
Lexaria Bioscience Corp. Discusses Demonstration of Improved Oral Delivery for Antiviral Drugs with The Stock Day Podcast

Lexaria Bioscience Corp. Discusses Demonstration of Improved Oral Delivery for Antiviral Drugs with The Stock Day Podcast

Phoenix, Arizona--(Newsfile Corp. - December 8, 2020) - The Stock Day Podcast welcomed Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX), the developer of DehydraTECH™, a proprietary drug delivery technology that improves the way active pharmaceutical ingredients (APIs) enter the bloodstream. CEO of the Company, Chris Bunka, joined Stock ... Read More...
Lexaria Bioscience Sells Non-Pharmaceutical THC-Related Assets for CDN$3.85M

Lexaria Bioscience Sells Non-Pharmaceutical THC-Related Assets for CDN$3.85M

Asset Sale in Preparation for US National Securities Exchange ListingKELOWNA, BC / ACCESSWIRE / November 19, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in oral drug delivery platforms, has entered a definitive asset purchase agreement (the "Agreement"), through its wholly owned s... Read More...
Lexaria Bioscience Extends Warrant Term

Lexaria Bioscience Extends Warrant Term

KELOWNA, BC / ACCESSWIRE / October 26, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator in oral drug delivery platforms, has determined to extend the term of an aggregate 1,823,745 share purchase warrants (the "Warrants"), which were issued pursuant to a private placement of units.The... Read More...
Lexaria Bioscience Supports Corporate Growth Initiatives by its Licensee, Cannadips CBD by the Boldt Runners Corporation

Lexaria Bioscience Supports Corporate Growth Initiatives by its Licensee, Cannadips CBD by the Boldt Runners Corporation

KELOWNA, BC / ACCESSWIRE / September 16, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, proudly supports the corporate growth initiatives underway by its DehydraTECHTM licensee, Boldt Runners Corporation ("Boldt Runners"), owners of the Cannadips CBD bran... Read More...
Lexaria BioScience Receives Ethics Board Approval to Conduct Exploratory Clinical Study using Cannabidiol for Blood Pressure Reduction

Lexaria BioScience Receives Ethics Board Approval to Conduct Exploratory Clinical Study using Cannabidiol for Blood Pressure Reduction

Complements previously published data that cites Lexaria's TurboCBD to demonstrate a significant 5% reduction in mean arterial blood pressure KELOWNA, BC / ACCESSWIRE / July 28, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announced that it has received... Read More...
Lexaria Bioscience Applies for NIH Grant for COVID-19 Therapy Studies and Receives New Expanded Health Canada License

Lexaria Bioscience Applies for NIH Grant for COVID-19 Therapy Studies and Receives New Expanded Health Canada License

KELOWNA, BC / ACCESSWIRE / June 18, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has submitted a grant application to the U.S. National Institutes of Health (NIH) entitled "In vitro and in vivo animal exploratory pharmacokinetic and prelimin... Read More...
Lexaria Bioscience Expands Pharmaceutical Division to Include Lipophilic Antiviral Active Molecules for COVID-19 Treatment

Lexaria Bioscience Expands Pharmaceutical Division to Include Lipophilic Antiviral Active Molecules for COVID-19 Treatment

KELOWNA, BRITISH COLUMBIA / ACCESSWIRE / March 23, 2020 / Lexaria Bioscience Corp. (LXRP)(LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, has expanded the scope and activities of its 100%-owned subsidiary Lexaria Pharmaceutical Corp., to investigate how Lexaria's patented DehydraTECHTM drug delivery te... Read More...
Lexaria Bioscience Begins Coronavirus COVID-19 Drug Delivery Program

Lexaria Bioscience Begins Coronavirus COVID-19 Drug Delivery Program

KELOWNA, BC / ACCESSWIRE / March 19, 2020 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery technology, announces it is commencing a program, in collaboration with leading laboratories in Canada and the USA, to study the benefits of Lexaria's DehydraTECHTM drug delivery platform f... Read More...
Industry Solutions from Lexaria's DehydraTECHTM Hemp and Cannabis Powders

Industry Solutions from Lexaria’s DehydraTECHTM Hemp and Cannabis Powders

KELOWNA, BC / ACCESSWIRE / February 13, 2020 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that its DehydraTECHTM-enabled CBD infused powders are now available for sale across the USA to businesses wanting to produce topicals and edibles with clinically p... Read More...
Lexaria Bioscience Corp. and Cannadips Cannabis Announce Expanded Relationship Into Cannabis Oral Pouch & Dip Category

Lexaria Bioscience Corp. and Cannadips Cannabis Announce Expanded Relationship Into Cannabis Oral Pouch & Dip Category

KELOWNA, BC / ACCESSWIRE / January 22, 2020 / Lexaria Bioscience Corp. (LXRP)(LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has reached a new definitive agreement to provide its patented DehydraTECHTM technology to Cannadips' cannabis products, both in its current California market,... Read More...
Lexaria Bioscience Corp. and Cannadips CBD Announce Definitive Technology Licensing agreement for CBD Oral Pouch & Dip Category

Lexaria Bioscience Corp. and Cannadips CBD Announce Definitive Technology Licensing agreement for CBD Oral Pouch & Dip Category

KELOWNA, BC / ACCESSWIRE / January 14, 2020 / Lexaria Bioscience Corp. (LXRP)(LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has reached a definitive agreement to provide its patented DehydraTECHTM technology to Cannadips CBD, the Original Smokeless CBD Dip Brand.Cannadips CBD is Ame... Read More...
Hill Street Sees 300% YOY Increase in Holiday Pack Sales and Provides Operational Update

Hill Street Sees 300% YOY Increase in Holiday Pack Sales and Provides Operational Update

Hill Street's Entertainer Pack at major retailers in time for Christmas and New Year'sToronto, Ontario--(Newsfile Corp. - December 23, 2019) - Hill Street Beverage Company Inc. (TSXV: BEER) ("Hill Street" or the "Company"), is pleased to announce the launch of its new Entertainer's Pack of alcohol-free wines has achieved national distribu... Read More...
Pure Ratios CEO Chad Conner Releases 15-Part Video Series on Cannabis Medicine

Pure Ratios CEO Chad Conner Releases 15-Part Video Series on Cannabis Medicine

Pure Ratios Holdings, a subsidiary of 4Front Ventures Corp. (CSE:FFNT.CN)(OTCQX:FFNTF), continues its mission to educate the public on the science of cannabis with a video series about the endocannabinoid systemSAN DIEGO, CA / ACCESSWIRE / November 27, 2019 / Chad Conner, CEO and co-founder of the San Diego cannabis wellness brand, Pure R... Read More...
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Featured in NetworkNewsWire Publication Reporting on Momentous Advances in Drug-Delivery Innovation

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Featured in NetworkNewsWire Publication Reporting on Momentous Advances in Drug-Delivery Innovation

NEW YORK, Sept. 05, 2019 -- via NetworkWire — Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company for private and public entities.To view the full publication, titled “Innovative Drug-Delivery Sy... Read More...
Lexaria Bioscience Announces DehydraTECH Patent for Pharmaceutical Applications of Cannabinoids to Treat Certain Disease Conditions

Lexaria Bioscience Announces DehydraTECH Patent for Pharmaceutical Applications of Cannabinoids to Treat Certain Disease Conditions

Lexaria Bioscience Corp. CONNECT TO Lexaria Bioscience Corp. Tuesday, August 27, 2019 6:15 AM KELOWNA, BC / ACCESSWIRE / August 27, 2019 / Lexaria Bioscience Corp. (OTCQX:LXRP) (CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to an... Read More...
Lexaria Announces Commercial Launch of ChrgD+ Odorless, Flavorless, Water-Soluble Powdered Hemp Oil

Lexaria Announces Commercial Launch of ChrgD+ Odorless, Flavorless, Water-Soluble Powdered Hemp Oil

KELOWNA, BC / ACCESSWIRE / August 22, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the online commercial launch of ChrgD+, the industry’s most advanced water-soluble multi-spectrum hemp oil in a powdered format and empowered with Dehydra... Read More...
Lexaria's Appoints Former Altria Group Senior Executive and Operating Company Chief to Board of Directors

Lexaria’s Appoints Former Altria Group Senior Executive and Operating Company Chief to Board of Directors

KELOWNA, BC / ACCESSWIRE / August 14, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Brian Quigley to its board of directors. Mr. Quigley most recently spent 16 years at Altria Group, with 7 of those years spent as P... Read More...
Lexaria Bioscience Completes Initial Project with Canada’s National Research Council

Lexaria Bioscience Completes Initial Project with Canada’s National Research Council

No chemical modification or degradation of Active Pharmaceutical Ingredients evidenced using DehydraTECH after acidic pH stability testingStrategically significant absence of covalent-bonded New Molecular Entity creation using DehydraTECHKELOWNA, BC / ACCESSWIRE / August 8, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN), (the “Company” o... Read More...
Lexaria Bioscience Engages Integra Consulting Group to Provide Investor Relations Services

Lexaria Bioscience Engages Integra Consulting Group to Provide Investor Relations Services

KELOWNA, BC / ACCESSWIRE / August 2, 2019 / Lexaria Bioscience Corp. (LXX.CN) (LXRP) (“Lexaria” or the “Company”) announces it has retained Integra Consulting Group LLC (“Integra”) to provide investor relations services to the Company in compliance with regulatory guidelines.Integra partners with select underexposed and undervalued emergi... Read More...
Coming Soon.

Delayed data (1h)


Share this page